{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:27:59Z","timestamp":1788226079047,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-018-1194-9","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T06:02:26Z","timestamp":1547186546000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Ryo","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-8351","authenticated-orcid":false,"given":"Kiyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"issue":"6","key":"1194_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1194_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","volume":"50","author":"H Izzedine","year":"2007","unstructured":"Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50(2):203\u201318.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"1194_CR3","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21(8):1381\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1194_CR4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129\u201336.","journal-title":"N Engl J Med"},{"issue":"2","key":"1194_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46(2):439\u201348.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1194_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","volume":"73","author":"F Pfister","year":"2018","unstructured":"Pfister F, Amann K, Daniel C, Klewer M, Buttner A, Buttner HM. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Histopathology. 2018;73(6):990\u20131001.","journal-title":"Histopathology"},{"issue":"12","key":"1194_CR7","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol. 2017;28(12):2932\u201342.","journal-title":"Ann Oncol"},{"issue":"5","key":"1194_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1172\/JCI17423","volume":"111","author":"V Eremina","year":"2003","unstructured":"Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707\u201316.","journal-title":"J Clin Invest"},{"issue":"10","key":"1194_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1681\/ASN.2010030295","volume":"21","author":"K Sison","year":"2010","unstructured":"Sison K, Eremina V, Baelde H, Min W, Hirashima M, Fantus IG, Quaggin SE. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol. 2010;21(10):1691\u2013701.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"1194_CR10","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"B Vicky","year":"2018","unstructured":"Vicky B, Katarina MW, David K. Thrombotic Microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"1194_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1681\/ASN.2015101168","volume":"28","author":"PM Keita","year":"2017","unstructured":"Keita PM, Hideki Y, Masato K, Hirotaka I, Akira I, Takashige K, Kenichi K, Yukiko K, Naohiro T, Shoko O, Koichiro K, Tomomi E, Kazuwa N, Motoko Y, Masashi M, Kiyoshi M. Increase of Total nephron albumin filtration and reabsorption in diabetic nephropathy. J Am Soc Nephrol. 2017;28(1):278\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1194_CR12","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","volume":"66","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Mark AP. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857\u201368.","journal-title":"Am J Kidney Dis"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1194-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-1194-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-1194-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T19:08:42Z","timestamp":1578683322000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-1194-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,11]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1194"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-1194-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,11]]},"assertion":[{"value":"27 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A family of the participant signed a letter of informed consent to allow her data to be stored, as required by Shizuoka General Hospital.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from a family of the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"14"}}